Abstract:Brian Warnecke, 1 Misako Nagasaka 1, 2 1 Department of Medicine, University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, USA; 2 Department of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan Correspondence: Misako Nagasaka, Department of Medicine, University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, 92868, USA, Email One of the most common mutations seen in lung cancers are mutations in Kristen Rat Sarcoma Viral Oncogene Homolog (KRAS), observed in 25– 30% of patients with NSCLC. Mutations in KRAS result in oncogenesis via persistent activation of the MAPK/ERK pathways. Although once thought to be "undruggable", KRAS p.G12C inhibitors such as sotorasib and adagrasib have been developed. This paper focuses on adagrasib, the second KRAS p.G12C inhibitor to obtain regulatory approval by the FDA and describes the details on its study design, development and current place in therapy. Keywords: Kristen Rat Sarcoma Viral Oncogene Homolog, sotorasib, AMG510, MRTX849, KRYSTAL, CodeBreaK, brain penetration Oncogenic driver mutations are detected in approximately 60% of non-small cell lung cancers (NSCLC). 1 Next generation sequencing (NGS) enables the identification of mutations with therapeutic implications, allowing for the use of targeted agents. 2–4 The most common mutation, however, are mutations in Kristen Rat Sarcoma Viral Oncogene Homolog (KRAS) which are seen in approximately 25–30% of patients with NSCLC. 1,5 Notably, there is a vast heterogeneity within the subtypes of KRAS-mutated NSCLC, and prevalence rates can vary geographically. The most common KRAS mutation is the p.G12C mutation, characterized by a glycine-to-cysteine mutation at codon 12. This is estimated to be seen in 40% of patients with KRAS-mutated NSCLC. The next most common KRAS mutations are G12V (19%), and G12D (15%). 5,6 KRAS mutations have higher frequency in adenocarcinomas than squamous cell carcinomas, 37.2% vs 4.4%, respectively. 5 Patients who are current or former smokers are also more likely to harbor KRAS mutations compared to non-smokers, one study reporting 34% vs 6%, respectively. Within the smoking cohort, KRAS p.G12C is the most common mutation seen and observed in 41% of those patients. 7 The oncogenesis of KRAS-mutated NSCLC revolves around the MAPK/ERK biochemical cascade. KRAS is one of three isoforms within the RAS group of oncogenes. It is a GTPase protein located on the cell membrane and functions to directly interact with the downstream signaling MAPK/ERK pathways, which is vital for cell survival, growth, and differentiation. 8 In KRAS mutant cells, GTP-bound KRAS remains persistently active, triggering a downstream cascade of phosphorylation and kinase activation of MEK and ERK. ERK kinases translocate to the nucleus of the cell to aid in vital cell functions. In RAS-mutant human cancer cells, these proteins exhibit single amino-acid replacements primarily residing at G12 or Q61. Thus, these RAS-mutant cells remain GTP-bound, leading to persistently activated signaling of their downstream cascade allowing for oncogenesis. 9 Lung cancer is the main etiology of brain metastases, accounting for 40–50% of all brain metastases. 10 Up to 25–50% of patients with KRAS-mutated NSCLC are diagnosed with brain metastases. 11,12 The development of brain metastases in patients with KRAS-mutated NSCLC is associated with a worse overall survival (OS) and quality of life. CNS failures are seen more frequently when compared with patients without KRAS mutations. 11,13 KRAS mutations are not only seen in NSCLC. In addition, they can be observed in 90% of pancreatic cancers and 50% of colorectal cancers. 14,15 KRAS p.G12C mutations are also seen in approximately 3.2% of patients with colorectal cancer, 3.1% of patients with small bowel cancer, 3.3% of patients with appendiceal cancers, and 3.5% of patients with cancers of unknown primary. 16 Mutations in KRAS distinctly provide negative prognostic value for patients with gastrointestinal cancers too. Among patients diagnosed with metastatic colorectal cancer, KRAS mutations were correlated with inferior progression free survival (PFS) and OS, exhibiting a multivariate hazard ratio (HR) of 1.20 (95% confidence interval [CI] 1.02–1.42) and HR of 2.99 (95% CI 2.10–4.42), respectively. Specifically, in this cohort of patients, KRAS p.G12C mutations were associated with inferior OS in comparison to tumors without KRAS p.G12C mutations with an HR of 2.26 (95% CI 1.25–4.1). 15 As described above, the oncogenic potential KRAS mutations lie with its ability to constitutively acti -Abstract Truncated-

Prognostic value of KRAS G12C mutation in lung adenocarcinoma stratified by stages and radiological features

Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma

KRAS Mutation Subtypes Responded Differently to Combination Immunotherapy Via Disturbing Myeloid-Derived Suppressor Cells in Non-Small Cell Lung Cancer.

The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features

Dissecting the Clinical Characteristics and Treatment Outcomes Correlates of KRAS G12C-Mutated Non-Small Cell Lung Cancer

Mutations in KRAS Codon 12 Predict Poor Survival in Chinese Patients with Metastatic Colorectal Cancer.

The histopathological spectrum and molecular changes associated with KRAS G12C mutation in non-small cell lung carcinoma

Assessing the significance of KRAS G12C mutation: Clinicopathologic features, treatments, and survival outcomes in a real-world KRAS mutant non-small cell lung cancer cohort.

Abstract 102: Clinicopathological and Molecular Characteristics, Treatment Patterns, and Outcomes in Patients with KRAS P.g12c-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC) in the AACR Project GENIE Database

The distribution of genetic mutations correlated with resistance to KRASG12C inhibitors in Chinese patients with lung cancer.

P1.02-047 Mutational Features and Prognosis of Non-Small-Cell Lung Cancer Harboring RAS Mutations

The Prevalence and Prognostic Significance of KRAS Mutation Subtypes in Lung Adenocarcinomas from Chinese Populations

A Retrospective Observational Study of the Natural History of Advanced Non-Small-cell Lung Cancer in Patients with KRAS P.g12c Mutated or Wild-Type Disease.

Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer

A retrospective analysis of the prognostic impact of KRAS G12D mutation in patients with RAS -mutated metastatic colorectal cancer.

Effects of different KRAS mutants and Ki67 expression on diagnosis and prognosis in lung adenocarcinoma

Molecular Characteristics and the Effect of KRAS Mutation on the Prognosis of Immunotherapy in Non-Small Cell Lung Cancer in Xinjiang, China

Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy

Clinicopathological Features and Prognosis of Lung Adenocarcinoma Patients With K-RAS Gene Mutation.

Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy

Real-World Study of Characteristics and Treatment Outcomes among Patients with KRAS P.g12c-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer